Clinical trial Recruiting at 1 site Interventional Ages 18 to 65

Chiropractic care to reduce episodic migraine attacks.

Official title: Chiropractic Care for Episodic Migraine

Run by Brigham and Women's Hospital · NCT06229834 · Data updated 2026-11-12

This pilot will test whether a 14-visit chiropractic care program, compared with headache health education plus usual care, can reduce migraine days and severity in adults with episodic migraine.

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment60 (estimated)
SponsorBrigham and Women's Hospital
Academic / other
Locations1 site (Boston, Massachusetts)
StatusRecruiting
StartedMarch 22, 2025
Main results expectedApril 1, 2027
Study endsApril 30, 2027
Registry record updatedJune 26, 2026
Trial IDNCT06229834 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–65 with a confirmed diagnosis of episodic migraine (4–13 migraine days per month), at least one year of migraine history, stable relevant medications for ≥2 months, English fluency, and access to a smartphone or computer are ideal candidates.

Probably not a fit

Patients with chronic migraine (>15 headache days per month), unstable medication regimens, inability to attend in-person chiropractic visits, or lacking English proficiency or required technology are unlikely to benefit from this pilot.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a two-arm, pilot randomized attention-controlled trial at two academic sites enrolling 60 adults with episodic migraine. Participants are randomized to 14 visits of multimodal chiropractic care delivered over 15 weeks or to 14 brief virtual headache health education sessions, with both arms receiving usual medical care. The trial will train chiropractors at established clinics and collect feasibility, safety, and preliminary effectiveness data to inform a larger pragmatic effectiveness trial. Key outcomes include migraine frequency, severity, and disability measured during and after the intervention.

Why it matters

Potential benefit: If successful, the intervention could reduce the number and severity of migraine attacks and provide a validated non-drug treatment option for episodic migraine.

How similar studies have gone: Previous research on manual therapies and multimodal chiropractic approaches for headache has been mixed but occasionally promising, so this approach is somewhat supported but not yet definitively proven.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria

* Age 18-65 years
* Confirmed diagnosis of migraine with or without aura which does not meet criteria for chronic migraine according to the International Classification for -Headache Disorders (ICHD)-3 guidelines at the screening visit with the study physician
* History of migraines dating for at least one year
* Completion of at least 26 headache diary days out of 28
* Confirmed migraine frequency ≥4 to ≤13 days per month during a run-in period
* If use of medication is applicable, dose must be stable for 2 months prior to study enrollment
* If use of medication for non-migraine pain condition is applicable (with the exception of episodic tension type headache), dose must be stable for 2 months prior to study enrollment
* Willing and able to complete all study procedures and be randomized to either of the two intervention groups
* Fluency in English
* Confirmed access to and proficiency with use of a smartphone, computer, and/or tablet
* Working email address or willingness to create an email account for the study

Exclusion Criteria

* Non-Veterans (VAMC only)
* Received botulinum toxin treatment for headache and/or neck pain within the 4 months prior to the start of the baseline phase
* Received chiropractic care for any condition within the 3 months prior to the start of the baseline phase
* Received behavioral interventions (e.g., cognitive behavioral therapy, acceptance and commitment therapy, mindfulness, relaxation techniques, hypnosis) within the past 3 months)
* Used neuromodulation (i.e., "headache devices"), procedures for migraine prevention within the 2 months before the baseline period, or investigational medications or headache devices for at least 90 days prior to screening
* Diagnosis of medication overuse headache according to the ICHD-3 guidelines at the screening visit with the study physician
* Traumatic Brain Injury ≤ 1 year before screening visit or worsening of migraine as noted by the screening study physician
* Head or neck trauma within the past year causing neurological or musculoskeletal signs or symptoms requiring treatment
* Any medical, neurologic, or psychiatric condition that the screening study physician deems would lead to difficulty complying with the protocol or negatively impact the safety profile of the interventions
* Psychiatric hospitalization in the last 6 months
* Receiving hospice or palliative care
* History of carotid or vertebral artery dissection
* Presence of carotid bruits
* Presence of contraindications (relative or absolute) for spinal manipulation or mobilization where these procedures cannot be modified for safe administration and are consistent with those published by the World Health Organization (WHO) guidelines, including but not limited to:
* Local spinal hypermobility/instability
* Conditions causing general spinal hypermobility, such as Marfan, Ehlers-Danlos syndrome, and Osteogenesis imperfecta
* Malignancy of the spine or spinal cord
* Frank disc herniation with signs of progressive neurological deficit
* Spinal or intracanalicular hematomas Inflammatory spondyloarthropathies such as rheumatoid arthritis
* Spinal fractures or dislocations
* Avascular necrosis in an area of proposed joint manipulation
* Bone-weakening disorders affecting the spine, such as benign bone tumors, infection, or osteoporosis
* Vertebrobasilar insufficiency syndrome
* Aneurysm involving a major blood vessel in an area of potential joint manipulation
* History of stroke
* Anticoagulant therapy or blood disorders cause significant bleeding tendency
* Cervical spine congenital anomalies that affect the stability or neurologic integrity of the individual or history of cervical spine surgery
* Either self-reported current alcohol or substance use disorder or current alcohol or substance use disorder documented by a treating medical provider within the past 6 months
* Hormone replacement therapy for less than six months, or if prescriptions greater than 6 months in duration must be at a stable dose
* Significant cognitive impairment that would impair participation in the trial
* Currently pregnant or intention to become pregnant within the next six months

Where it's running

  • Osher Center for Integrative Health, Mass General Brigham
    Boston, Massachusetts, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Gou-Teng-San (GTS) for adults with episodic migraine

    This trial will test whether the herbal formula Gou-Teng-San (GTS) can reduce migraine attacks and symptoms in adults with episodic migraine.

    Recruiting Phase 3 China Medical University, Taiwan · Taichung, South · NCT07496034

  • Real-world use of anti-CGRP medicines for preventing migraine

    This project will follow people with episodic or chronic migraine who start anti-CGRP medicines to see if the treatments reduce migraine frequency and side effects over two years.

    Recruiting at 25 sites Hospital Universitari Vall d'Hebron Research Institute · Miami, Florida and 25 other locations · NCT07159750

  • i-NEED: New migraine drugs database

    This project will collect real-life data to see how new migraine treatments—anti‑CGRP antibodies, gepants, ditans, and a sumatriptan‑naproxen combo—work and how well adults with episodic or chronic migraine tolerate them.

    Recruiting at 2 sites IRCCS San Raffaele Roma · Milan, Italy and 1 other locations · NCT07103694

  • Effects of Atogepant on Neurophysiology and Biomolecules in Migraine

    This study is testing if a new migraine medication called atogepant can change brain activity and biochemistry in people who have frequent migraines.

    Recruiting IRCCS National Neurological Institute "C. Mondino" Foundation · Pavia, PAVIA · NCT06882122

  • Analyzing CGRP Levels in Migraine Patients by Age and Sex

    This study looks at the levels of a substance linked to migraines in people with migraines and healthy individuals to see how age and sex might affect treatment responses.

    Recruiting Hospital Universitari Vall d'Hebron Research Institute · Barcelona, Barcelona · NCT06674772

  • Assessing the safety and effectiveness of Atogepant for migraine prevention in Korean adults

    This study is testing how well and safely Atogepant works for preventing migraines in Korean adults who have chronic or episodic migraines.

    Recruiting at 36 sites AbbVie · Busan, Busan Gwang Yeogsi and 35 other locations · NCT06603558

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.